Despite hefty price, Immunocore's Kimmtrak will dominate uveal melanoma market

8 February 2022

The recent US Food and Drug Administration approval of the first T-cell receptor (TCR) therapy, UK biotech Immunocore’s (Nasdaq: IMCR) Kimmtrak (tebentafusp-tebn), for the treatment of uveal melanoma offers such a clear benefit to patients that it will become the standard of care in the USA, says analytics firm GlobalData.

GlobalData estimates the annual cost of treatment with Kimmtrak to be extremely high, between $400,000 and $500,000 in the USA.

Uveal melanoma is a rare cancer of the eye, which in the majority of patients is localized. However, upon becoming metastatic (mUM), the prognosis is dismal, with patients surviving only a year on average.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK